SCHEMBL5548416

SCHEMBL5548416

CCCC(=O)Cc1ccc([O])cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IAPP P10997 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HPGD P15428 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HSD17B10 Q99714 1/20 0.41
POLB P06746 1/20 0.37
APEX1 P27695 1/20 0.37
HSD17B3 P37058 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
PDE4A P27815 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HIF1A Q16665 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4541922 0.85 ALDH1A1 (0.48) IAPPTDP1L3MBTL1HPGDALDH1A1
SCHEMBL106914 0.83 CA2 (0.54) IAPPTDP1L3MBTL1ALDH1A1HSD17B10
SCHEMBL1411319 0.83 L3MBTL1 (0.62) IAPPTDP1L3MBTL1HPGDALDH1A1
SCHEMBL5539303 0.83 IAPP (0.40) IAPPTDP1L3MBTL1HPGDALDH1A1
SCHEMBL8833730 0.82 TDP1 (0.56) IAPPTDP1L3MBTL1HPGDHSD17B10
SCHEMBL7256785 0.82 ALDH1A1 (0.49) IAPPTDP1L3MBTL1HPGDALDH1A1
SCHEMBL9300862 0.82 KMT2A (0.50) IAPPTDP1L3MBTL1HPGDPOLB
SCHEMBL107900 0.81 L3MBTL1 (0.59) TDP1L3MBTL1HPGDALDH1A1POLB
SCHEMBL15435250 0.80 NR1H4 (0.47) IAPPTDP1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL5650048 0.80 ALDH1A1 (0.59) TDP1L3MBTL1ALDH1A1POLBAPEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 IAPP 4885/4885TDP1 4666/4885L3MBTL1 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.